Tamara Fountain Buys Shares of RxSight, Inc.
Tamara Fountain has increased her stake in RxSight, Inc. with a recent purchase.
Key Points
- Tamara Fountain bought 37,037 shares of RxSight, Inc. on June 17, 2026, without a planned transaction code.
- RxSight, Inc. trades at $4.73 with a market cap of approximately $195.8 million and a beta of 1.134.
- Analysts maintain varied ratings, with Needham reiterating a buy and a target price of $11.00.
Tamara Fountain has recently increased her stake in RxSight, Inc. (NasdaqGM: RXST) by purchasing 37,037 shares on June 17, 2026. This transaction was not part of a pre-planned trading program.
Other Institutional Activity in RxSight, Inc.
BlackRock, Inc. grew its holdings in RxSight by 482,086 shares, ending with 3,187,092 shares valued at roughly $19.63 million. Millennium Management LLC slightly trimmed its position by 69,579 shares, holding 2,059,459 shares worth about $12.69 million. Artisan Partners Limited Partnership also reduced its stake by 98,580 shares, leaving it with 2,058,684 shares valued at approximately $12.68 million. Meanwhile, D. E. Shaw & Co., Inc. increased its holdings by 75,903 shares, reaching a total of 1,959,732 shares valued at about $12.07 million.
RxSight, Inc. Stock Snapshot
Shares of RxSight, Inc. are trading around $4.73 on the NasdaqGM. The company has a market capitalization of about $195.8 million and a beta of 1.134, indicating moderate volatility compared to the market. The stock has seen a 52-week range between $4.48 and $14.29. Its 50-day moving average stands at $6.09, while the 200-day moving average is $8.36. RxSight has a strong current ratio of 10.2 and a quick ratio of 8.779, but a higher debt-to-equity ratio of 4.05.
Recent Earnings
RxSight reported revenue of $127.5 million, with a decline in revenue growth at -18.5%. The company posted a net margin of -36.6% and a return on equity of -17.1%. Its forward P/E ratio is not meaningful due to negative earnings per share of -$1.13. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at RxSight, Inc.
On June 17, 2026, several insiders, including Tamara Fountain, Juliet Tammenoms Bakker, Robert Keith Warner, Robert Palmisano, William Link, Ph.D., Shweta Maniar, and Jesse Anderson Corley, each purchased 37,037 shares of RxSight, Inc. These transactions were not part of pre-planned trading programs.
Analysts Set New Price Targets
On May 7, 2026, Wells Fargo maintained a hold rating with a price target of $9.00, while Needham reiterated its buy rating with a target of $11.00. Stifel and UBS also maintained hold ratings with price targets of $9.00. Piper Sandler reiterated a hold rating with a target of $11.00 on January 20, 2026.
About RxSight, Inc.
RxSight, Inc. is a medical technology company based in Aliso Viejo, California. It specializes in the development and sale of light adjustable intraocular lenses (LAL) used in cataract surgery. The company's RxSight system allows doctors to customize patients' vision after surgery using a special lens and UV light delivery device. Led by CEO Dr. Ronald M. Kurtz, the company employs around 461 people.
Bottom Line
Tamara Fountain's recent purchase of RxSight shares highlights ongoing interest in the company's potential. With a current trading price of $4.73, RxSight is navigating challenges in revenue growth and profitability. Analyst ratings remain mixed, with some maintaining hold positions while others see potential for growth. As always, investors should remember that insider transactions and analyst ratings are just parts of a broader evaluation process.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.